$14.07
4.29% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Tyra Bioscience Stock price

$14.07
-1.93 12.06% 1M
-1.38 8.93% 6M
+0.22 1.59% YTD
+0.07 0.50% 1Y
-0.44 3.03% 3Y
-11.93 45.88% 5Y
-11.93 45.88% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.63 4.29%
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Key metrics

Market capitalization $743.91m
Enterprise Value $390.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-100.09m
Free Cash Flow (TTM) Free Cash Flow $-64.98m
Cash position $360.13m
EPS (TTM) EPS $-1.61
P/E forward negative
Short interest 9.32%
Show more

Is Tyra Bioscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Tyra Bioscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

Buy
100%

Financial data from Tyra Bioscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.48 0.48
45% 45%
-
-0.48 -0.48
45% 45%
-
- Selling and Administrative Expenses 21 21
26% 26%
-
- Research and Development Expense 78 78
50% 50%
-
-100 -100
44% 44%
-
- Depreciation and Amortization 0.48 0.48
45% 45%
-
EBIT (Operating Income) EBIT -100 -100
44% 44%
-
Net Profit -84 -84
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tyra Bioscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tyra Bioscience Stock News

Neutral
24/7 Wall Street
about one month ago
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
Neutral
PRNewsWire
about 2 months ago
CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Con...
Neutral
PRNewsWire
about 2 months ago
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif. , Nov. 7, 2024...
More Tyra Bioscience News

Company Profile

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Head office United States
CEO Todd Harris
Employees 49
Founded 2018
Website www.tyra.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today